Differences between Community - and Hospital - acquired urinary tract infections in a tertiary care hospital.


Journal

The new microbiologica
ISSN: 1121-7138
Titre abrégé: New Microbiol
Pays: Italy
ID NLM: 9516291

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 04 04 2020
accepted: 04 04 2020
pubmed: 10 12 2019
medline: 22 4 2020
entrez: 10 12 2019
Statut: ppublish

Résumé

The aim of this retrospective study was to highlight the differences in antibiotic resistance between Hospital-acquired and Community-acquired urinary tract infections (UTIs). Antimicrobial UTIs resistance data were collected from March 2011 to March 2018. Uropathogens were identified from 41,715 patients using routine laboratory methods. Differences in antibiotic resistance between Hospital and Community (non-hospitalized) patients were statistically validated. Odds ratio (OR) and p-values was used to determine whether a particular exposure (hospitalization) was a risk factor for a particular outcome (higher antibiotic resistance). We reported a general increase of unnecessary urine cultures in both community and hospital patients. The most representative microorganism isolated from Community (58.2%) and Hospital (47.6%) was E. coli. UTIs causative bacteria in hospitalized patients was more than twice as resistant to Trimetoprim/sulphamethoxazole (OR 2.26) and Imipenem (OR 2.56), for Gram-positive and Gram-negative, respectively, than in Community patients. Nitrofurantoin was the only agent without differences in resistance rate between community and hospital UTIs. Therefore, physicians could use it as a definitive therapy for uncomplicated cystitis and as a prophylactic agent for recurrent uncomplicated cystitis. With this work we provided a general protocol applicable by physicians to select the most suitable, if necessary, UTIs empiric treatment.

Identifiants

pubmed: 31814033
pii: 496N128

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-21

Auteurs

Alessio Mancini (A)

School of Biosciences and Veterinary Medicine, University of Camerino, 62032, Camerino Italy.

Sandra Pucciarelli (S)

School of Biosciences and Veterinary Medicine, University of Camerino, 62032, Camerino Italy.

Francesca Elena Lombardi (FE)

Facoltà di Medicina e Chirurgia, Università Politecnica delle Marche, P.zza Roma 22, 60121, Ancona, Italy.

Simone Barocci (S)

ASUR MARCHE AV2 Senigallia, O.U. Clinical Pathology, via Cellini, 60019 Senigallia (AN), Italy.

Paola Pauri (P)

ASUR MARCHE AV2 Jesi, O.U. Clinical Pathology, Via Aldo Moro, 60035, Jesi (AN), Italy.

Stefano Lodolini (S)

ASUR MARCHE AV2 Senigallia, O.U. Clinical Pathology, via Cellini, 60019 Senigallia (AN), Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH